Identifying biomarkers that predict blood clots in ovarian cancer patients
Official title: Novel Biomarkers Predicting Blood Clots in Ovarian Cancer
Funded at University of Tx Md Anderson Can Ctr · NIH-10931748 · Data updated 2026-11-12
This study is looking at how ovarian cancer and chemotherapy might increase the risk of blood clots, and it aims to find specific markers in patients' tumors and blood that can help identify who is more likely to have this risk, so doctors can provide safer and more personalized treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 19, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $419,571 |
| NIH project number | 5R01CA275762-02 |
| Project ID | NIH-10931748 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are ovarian cancer patients who are receiving or have received neoadjuvant chemotherapy.
✕Less likely to help
Patients with ovarian cancer who are not undergoing chemotherapy or those with other underlying conditions that preclude participation may not benefit from this research.
What this research studies
This research investigates the risk of venous thromboembolism (VTE) in ovarian cancer patients, particularly those undergoing chemotherapy. By analyzing tumor specimens and blood samples from a cohort of patients, the study aims to identify novel biomarkers that indicate a higher risk of developing blood clots. The researchers will focus on cancer cell products, specifically looking at the role of mitochondria and podoplanin in increasing VTE risk. This approach seeks to improve patient safety by allowing for targeted anticoagulation therapy rather than a blanket approach for all patients.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment plans that reduce the risk of blood clots in ovarian cancer patients undergoing chemotherapy.
How similar studies have gone: Previous research has shown success in identifying risk factors for VTE in cancer patients, but this study's focus on tumor-specific biomarkers is a novel approach.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Afshar-Kharghan, Vahid — University of Tx Md Anderson Can Ctr
- Study coordinator: Afshar-Kharghan, Vahid
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.